missing translation for 'onlineSavingsMsg'
Learn More
Learn More
This item is not returnable.
View return policy
Description
The TM- β 1 antibody reacts with the 90-100-kDa β chain shared by the IL-2 and IL-15 receptors (IL-2R β , CD122). In the periphery, CD122 is expressed on CD8+ T lymphocytes, NK cells, NK-T cells, dendritic epidermal T cells, subsets of intraepithelial lymphocytes, and macrophages. Small subsets of fetal and adult thymocytes constitutively express CD122. CD122+ cells in the bone marrow include committed NK-cell progenitors. IL-2R β expression is upregulated by IL-2. CD122 is a transmembrane glycoprotein of the hematopoietin receptor superfamily which can combine with CD132 ( γc) alone or CD132 plus CD25 (IL-2R α ) to form intermediate or high-affinity IL-2 receptor complexes, respectively. The β chain of these complexes, CD122, is involved in signal transduction and immunoregulation. The TM- β 1 antibody blocks high affinity binding of IL-2 or IL-15 to IL-2R β .
The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.
Specifications
| CD122 | |
| Monoclonal | |
| 0.2mg/mL | |
| Il2rb; Il-2Rbeta; IL-2Rβ; IL-15Rbeta; IL-2/15 Receptor-beta; IL-2/15Rbeta | |
| Rat | |
| Affinity Purified | |
| RUO | |
| Mouse | |
| IgG2b κ |
| Flow Cytometry | |
| TM-Beta 1 | |
| Brilliant Violet 510 | |
| Aqueous buffered solution containing ≤0.09% sodium azide. | |
| Mouse IL-2Rβ Transfected Cell Line | |
| 50 μg | |
| Primary | |
| Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction